BCL-10 is an apoptotic regulatory molecule, of approximately 31 kDa
| Inventor | Institute |
|---|---|
| Ming-Qing Du | University College London (UCL) |
| SKU: | 151821 |
|---|---|
| Product description: | BCL-10 is an apoptotic regulatory molecule, of approximately 31 kDa. It was identified through its direct involvement in t(1:14) (p22;q32) of mucosa-associated lymphoid tissue (MALT) lymphoma. In B-cell follicles, BCL10 has been shown to be expressed abundantly in the germinal center B cells, moderately in the marginal zone, but only weakly in mantle zone B cells. This differential expression is an indicator of its importance in maturation and malignant transformation of human B-cells. BCL-10 contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Immunogen: | Full-length recombinant BCL-10 protein |
| Myeloma used: | NS0 |
| Cat. #: | 151821 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Apoptosis and autophagy;Cancer;Cell signaling and signal transduction;Metabolism |
| Application: | ELISA ; IHC ; WB |
| Target: | Bcl10 |
| Reactivity: | Human |
| Clone: | 151 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | BCL-10 is an apoptotic regulatory molecule, of approximately 31 kDa. It was identified through its direct involvement in t(1:14) (p22;q32) of mucosa-associated lymphoid tissue (MALT) lymphoma. In B-cell follicles, BCL10 has been shown to be expressed abundantly in the germinal center B cells, moderately in the marginal zone, but only weakly in mantle zone B cells. This differential expression is an indicator of its importance in maturation and malignant transformation of human B-cells. BCL-10 contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Shen et al. 2003. Blood. 102(4):1553-4. PMID: 12900354. Aberrant BCL10 nuclear expression in nasal NK/T-cell lymphoma. Ye et al. 2000. Am J Pathol. 157(4):1147-54. PMID: 11021819. BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. Du et al. 2000. Blood. 95(12):3885-90. PMID: 10845924. BCL10 gene mutation in lymphoma. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.